Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRU-D: Durvalumab + Tremelimumab in Ovarian Cancer
NCT03899610Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in ovarian cancer, sponsored by Yonsei University. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03899610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899610.